Clinical Trial

The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aimed to evaluate the conversion rate to curative-intent treatment in patients with unresectable stage IIIB-IIIC non-small cell lung cancer (NSCLC) following induction therapy with PD-1 blockade combined with chemotherapy, and to assess progression-free survival (PFS) in these patients who underwent curative-intent treatment .
Trial Details
NCT Number NCT06962189
Lead Sponsor Zhejiang University
Conditions Non Small Cell Lung Cancer (Stage III)
Enrollment 39 participants
Start Date 2025-05-15
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-08